282 related articles for article (PubMed ID: 30095246)
1. Novel Scaffolds for Dual Specificity Tyrosine-Phosphorylation-Regulated Kinase (DYRK1A) Inhibitors.
Czarna A; Wang J; Zelencova D; Liu Y; Deng X; Choi HG; Zhang T; Zhou W; Chang JW; Kildalsen H; Seternes OM; Gray NS; Engh RA; Rothweiler U
J Med Chem; 2018 Sep; 61(17):7560-7572. PubMed ID: 30095246
[TBL] [Abstract][Full Text] [Related]
2. A novel DYRK1A (dual specificity tyrosine phosphorylation-regulated kinase 1A) inhibitor for the treatment of Alzheimer's disease: effect on Tau and amyloid pathologies in vitro.
Coutadeur S; Benyamine H; Delalonde L; de Oliveira C; Leblond B; Foucourt A; Besson T; Casagrande AS; Taverne T; Girard A; Pando MP; Désiré L
J Neurochem; 2015 May; 133(3):440-51. PubMed ID: 25556849
[TBL] [Abstract][Full Text] [Related]
3. Small Molecule Inhibitors of DYRK1A Identified by Computational and Experimental Approaches.
Yoon HR; Balupuri A; Choi KE; Kang NS
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32957634
[TBL] [Abstract][Full Text] [Related]
4. 10-iodo-11H-indolo[3,2-c]quinoline-6-carboxylic acids are selective inhibitors of DYRK1A.
Falke H; Chaikuad A; Becker A; Loaëc N; Lozach O; Abu Jhaisha S; Becker W; Jones PG; Preu L; Baumann K; Knapp S; Meijer L; Kunick C
J Med Chem; 2015 Apr; 58(7):3131-43. PubMed ID: 25730262
[TBL] [Abstract][Full Text] [Related]
5. Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase 1A (DYRK1A) Inhibitors as Potential Therapeutics.
Jarhad DB; Mashelkar KK; Kim HR; Noh M; Jeong LS
J Med Chem; 2018 Nov; 61(22):9791-9810. PubMed ID: 29985601
[TBL] [Abstract][Full Text] [Related]
6. Discovery and Characterization of Selective and Ligand-Efficient DYRK Inhibitors.
Henderson SH; Sorrell F; Bennett J; Fedorov O; Hanley MT; Godoi PH; Ruela de Sousa R; Robinson S; Ashall-Kelly A; Hopkins Navratilova I; Walter DS; Elkins JM; Ward SE
J Med Chem; 2021 Aug; 64(15):11709-11728. PubMed ID: 34342227
[TBL] [Abstract][Full Text] [Related]
7. Development of a novel selective inhibitor of the Down syndrome-related kinase Dyrk1A.
Ogawa Y; Nonaka Y; Goto T; Ohnishi E; Hiramatsu T; Kii I; Yoshida M; Ikura T; Onogi H; Shibuya H; Hosoya T; Ito N; Hagiwara M
Nat Commun; 2010 Oct; 1():86. PubMed ID: 20981014
[TBL] [Abstract][Full Text] [Related]
8. Selective inhibition of the kinase DYRK1A by targeting its folding process.
Kii I; Sumida Y; Goto T; Sonamoto R; Okuno Y; Yoshida S; Kato-Sumida T; Koike Y; Abe M; Nonaka Y; Ikura T; Ito N; Shibuya H; Hosoya T; Hagiwara M
Nat Commun; 2016 Apr; 7():11391. PubMed ID: 27102360
[TBL] [Abstract][Full Text] [Related]
9. Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.
Nguyen TL; Fruit C; Hérault Y; Meijer L; Besson T
Expert Opin Ther Pat; 2017 Nov; 27(11):1183-1199. PubMed ID: 28766366
[TBL] [Abstract][Full Text] [Related]
10. Mechanism of dual specificity kinase activity of DYRK1A.
Walte A; Rüben K; Birner-Gruenberger R; Preisinger C; Bamberg-Lemper S; Hilz N; Bracher F; Becker W
FEBS J; 2013 Sep; 280(18):4495-511. PubMed ID: 23809146
[TBL] [Abstract][Full Text] [Related]
11. Activation, regulation, and inhibition of DYRK1A.
Becker W; Sippl W
FEBS J; 2011 Jan; 278(2):246-56. PubMed ID: 21126318
[TBL] [Abstract][Full Text] [Related]
12. Novel selective thiadiazine DYRK1A inhibitor lead scaffold with human pancreatic β-cell proliferation activity.
Kumar K; Man-Un Ung P; Wang P; Wang H; Li H; Andrews MK; Stewart AF; Schlessinger A; DeVita RJ
Eur J Med Chem; 2018 Sep; 157():1005-1016. PubMed ID: 30170319
[TBL] [Abstract][Full Text] [Related]
13. Systematic diversification of benzylidene heterocycles yields novel inhibitor scaffolds selective for Dyrk1A, Clk1 and CK2.
Mariano M; Hartmann RW; Engel M
Eur J Med Chem; 2016 Apr; 112():209-216. PubMed ID: 26896709
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis and biological evaluation of harmine derivatives as potent GSK-3β/DYRK1A dual inhibitors for the treatment of Alzheimer's disease.
Liu W; Liu X; Tian L; Gao Y; Liu W; Chen H; Jiang X; Xu Z; Ding H; Zhao Q
Eur J Med Chem; 2021 Oct; 222():113554. PubMed ID: 34098466
[TBL] [Abstract][Full Text] [Related]
15. Leucettine L41, a DYRK1A-preferential DYRKs/CLKs inhibitor, prevents memory impairments and neurotoxicity induced by oligomeric Aβ25-35 peptide administration in mice.
Naert G; Ferré V; Meunier J; Keller E; Malmström S; Givalois L; Carreaux F; Bazureau JP; Maurice T
Eur Neuropsychopharmacol; 2015 Nov; 25(11):2170-82. PubMed ID: 26381812
[TBL] [Abstract][Full Text] [Related]
16. Development of Kinase-Selective, Harmine-Based DYRK1A Inhibitors that Induce Pancreatic Human β-Cell Proliferation.
Kumar K; Wang P; Sanchez R; Swartz EA; Stewart AF; DeVita RJ
J Med Chem; 2018 Sep; 61(17):7687-7699. PubMed ID: 30059217
[TBL] [Abstract][Full Text] [Related]
17. Indole-3-Carbonitriles as DYRK1A Inhibitors by Fragment-Based Drug Design.
Meine R; Becker W; Falke H; Preu L; Loaëc N; Meijer L; Kunick C
Molecules; 2018 Jan; 23(2):. PubMed ID: 29364148
[TBL] [Abstract][Full Text] [Related]
18. Discovery of a novel chemotype as DYRK1A inhibitors against Alzheimer's disease: Computational modeling and biological evaluation.
Qiu N; Qian C; Guo T; Wang Y; Jin H; Yao M; Li M; Guo T; Lv Y; Si X; Wu S; Wang H; Zhang X; Xia J
Int J Biol Macromol; 2024 Jun; 269(Pt 1):132024. PubMed ID: 38704072
[TBL] [Abstract][Full Text] [Related]
19. New pyrido[3,4-g]quinazoline derivatives as CLK1 and DYRK1A inhibitors: synthesis, biological evaluation and binding mode analysis.
Tazarki H; Zeinyeh W; Esvan YJ; Knapp S; Chatterjee D; Schröder M; Joerger AC; Khiari J; Josselin B; Baratte B; Bach S; Ruchaud S; Anizon F; Giraud F; Moreau P
Eur J Med Chem; 2019 Mar; 166():304-317. PubMed ID: 30731399
[TBL] [Abstract][Full Text] [Related]
20. DYRK1A kinase inhibitors with emphasis on cancer.
Ionescu A; Dufrasne F; Gelbcke M; Jabin I; Kiss R; Lamoral-Theys D
Mini Rev Med Chem; 2012 Nov; 12(13):1315-29. PubMed ID: 23016545
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
